PG 2025: Pulmonary Literature Review and Interactive Complex Case Presentations (PG)-Rogers MOC 2025 PrePost Course Assessment revised2 copy

Rogers MOC 2025 PrePost Course Assessment revised2 copy

Pdf Summary

The 2025 Rogers Asthma Maintenance of Certification (MOC) course, led by Dr. Linda Rogers, focuses on advances in severe asthma management. The course aims to update learners on the role of anti-inflammatory reliever therapies, risks associated with high-dose inhaled corticosteroids (ICS), recent asthma biologics data, the concept of asthma clinical remission, and emerging potential treatments such as GLP-1 therapies.<br /><br />A pre-course multiple-choice question addresses the 2025 Global Initiative for Asthma (GINA) guidance on treating mild intermittent asthma (Step 1). The correct answer highlights that ICS-formoterol reliever therapy reduces exacerbations more effectively than ICS-albuterol, with similar symptom control. This is based on a 2025 JAMA systematic review showing ICS-formoterol reduced severe exacerbation risk by 10.3%, compared to 4.7% with ICS-SABA and better symptom control than short-acting beta-agonists (SABA) alone.<br /><br />The post-course assessment question focuses on adverse effects of inhaled corticosteroids. The correct response notes that cohort studies have linked high-dose ICS to several adverse outcomes, including osteoporosis, major cardiovascular events, type 2 diabetes, pulmonary embolism, and pneumonia, even after controlling for oral corticosteroid exposure. This was supported by two large 2025 observational cohort studies published in the American Journal of Respiratory and Critical Care Medicine and JACI in Practice.<br /><br />In summary, this MOC activity updates clinicians on evolving asthma treatments emphasizing safer, more effective reliever options and underscores risks with high-dose ICS therapy. It also introduces novel potential treatments, aligning with current evidence to optimize severe asthma care and minimize adverse effects.

Keywords

Rogers Asthma MOC 2025

severe asthma management

anti-inflammatory reliever therapies

high-dose inhaled corticosteroids risks

asthma biologics data 2025

asthma clinical remission

GLP-1 therapies asthma

ICS-formoterol reliever therapy

adverse effects inhaled corticosteroids

GINA 2025 mild intermittent asthma